They are funded through until at least mid next year by which time they will have results of three phase 2 trials. The most important milestone this year is the interim data release for SNT 5505 in myelofibrosis - and a presentation at ASH in December. Spec buy and hold until then in my opinion.
Ann: Phase 2 Trial Reaches 50% Recruitment, page-5
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
